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Abstract
Background:   Gene disruption by targeted integration of transfected constructs becomes
increasingly popular for studies of gene function. The chicken B cell line DT40 has been widely used
as a model for gene knock-outs due to its high targeted integration activity. Disruption of multiple
genes and complementation of the phenotypes is, however, restricted by the number of available
selectable marker genes. It is therefore highly desirable to recycle the selectable markers using a
site-specific recombination system like Cre/loxP.
Results:  We constructed three plasmid vectors (neoR, puroR and bsr), which carry selectable
marker genes flanked by two different mutant loxP sites. After stable transfection, the marker
genes can be excised from the genome by transient induction of Cre recombinase expression. This
excision converts the two mutant loxP sites to an inactive double-mutant loxP. Furthermore we
constructed a versatile expression vector to clone cDNA expression cassettes between mutant
loxP sites. This vector can also be used to design knock-out constructs in which the floxed marker
gene is combined with a cDNA expression cassette. This construct enables gene knock-out and
complementation in a single step. Gene expression can subsequently be terminated by the Cre
mediated deletion of the cDNA expression cassette. This strategy is powerful for analyzing
essential genes, whose disruption brings lethality to the mutant cell.
Conclusions:  Mutant loxP vectors have been developed for the recycle of selectable markers and
conditional gene knock-out approaches. As the marker and the cDNA expression cassettes are
driven by the universally active and evolutionary conserved β -actin promoter, they can be used for
the selection of stable transfectants in a wide range of cell lines.
Background
Defined mutations can be introduced into embryonic
stem (ES) cells by homologous recombination and the ef-
fect of the mutation can be studied in animals derived
from these cells. Many genes are however essential for
embryonic development and a homozygous deletion re-
sult in non-viable embryos. Gene disruption in a cell line
can be an alternative to the production of a knock-out an-
imal. The chicken B cell line DT40 is popular for these
studies due to its high ratios of targeted to random inte-
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gration [1]. DT40 mutants have been used in the field of
B cell antigen receptor signaling, cell cycle regulation,
apoptosis, histon acetylation, homologous recombina-
tion and DNA repair [2]. Although mating of DT40
clones is not possible, multiple mutations can be accu-
mulated in the same cell clone by the step-wise transfec-
tion of knock-out constructs. This approach holds great
promise for the analysis of genetic networks, but it is cur-
rently limited by the inherent consumption of one se-
lectable marker for each introduced mutation.
The Cre-loxP recombination system of bacteriophage P1
has been employed for genetic manipulation of higher
eukaryotic cells [3]. Cre recombinase recognizes a 34
base pair (bp) Cre recombination signal sequence called
loxP, and can delete genes which are flanked by two loxP
sites in the same direction. The mutant loxP system,
which is composed of two different mutant loxP sites
(loxP_RE and loxP_LE), was first utilized for genetic
manipulation of tobacco [4]. This mutant loxP system
has been applied to mouse ES cell for site-specific inser-
tion mutagenesis [5]. While the standard loxP site has a
13 bp palindrome on both ends, 5 bp of the palindromic
sequences are mutated in loxP_RE and loxP_LE (Figure
1a). Cre recombinase can still recognize the mutant loxP
sites and delete the intervening region. During this proc-
ess loxP_RE and loxP_LE are converted to a new
loxP_RE+LE site, which is poorly recognized by Cre [5].
This has the advantage that genetic instability associated
with recutting of the remnant loxP_RE+LE site is mini-
mized.
Recombination of loxP sites can be achieved by transient
transfection of a Cre expression plasmid [6]. Alternative-
ly Cre recombination can be controlled by stable trans-
fection of an inducible Cre recombinase construct. A
tightly regulated Cre recombinase, MerCreMer is de-
signed as a fusion protein of Cre and the hormone-bind-
ing domains (HBDs) of the mutated estrogen receptor
(Mer) [7]. This Cre recombinase is active in the presence
of the Mer ligand, 4-hydroxy tamoxifen, but sequestered
in an inactive form by heat shock proteins in the absence
of the ligand. MerCreMer functions efficiently in DT40
cells [8] as well as in mammalian cell lines.
We have constructed three plasmid vectors containing
selectable marker cassettes flanked by mutant loxP sites.
Following integration into the genome of DT40 cell, the
marker cassettes are efficiently deleted, if MerCreMer is
induced by 4-hydroxy tamoxifen. Another vector con-
taining a cDNA expression cassette flanked by loxP sites
should be useful for conditional knock-outs.
Results
Vectors containing mutant loxP flanked marker cassettes
Mutant loxP vectors, pLoxNeo, pLoxPuro and pLoxBsr,
are designed respectively to have neomycin resistance
(neoR), puromycin resistance (puroR), blasticidin S re-
sistance (bsr) genes located between the loxP_RE and
loxP_LE (Figure 1b). All resistant markers are driven by
the chicken β -actin promoter. Transcription of the
pLoxNeo, pLoxPuro and pLoxBsr is terminated by an ar-
tificial polyA signal, the SV40 polyA signal and the HSV
tk polyA signal, respectively. These mutant loxP-flanked
selectable marker genes can be used as BamHI cassettes
in knock-out construct and expression constructs.
Knock-out constructs can be generated by cloning se-
quences from the 5' and the 3' end of the target locus into
the multiple cloning sites (MCS_1 and MCS_2) of the
mutant loxP vectors. An alternative strategy is to first
clone the 5' and 3' target locus sequences into the vector,
and then insert the selectable marker cassette into the
BamHI-compatible sites (BamHI [GGATCC], BglII [AG-
ATCT] or BclI [TGATCA]).
A primer derived from the marker gene can be used with
a primer derived from a sequence of the target locus
which was not included in the knock-out construct to
screen for targeted integration events. The sequences of
a suitable primer for each marker gene are given in Table
1I. These primers worked most reliable among a couple
of primers tested for PCR amplifications. Several at-
tempts to find primers suitable for PCR amplification in
the direction upstream of the β -actin promoter were un-
successful. Attempts to amplify through the β -actin pro-
moter also failed. We suspect that this is due to the
extremely GC-rich sequence of β -actin promoter.
Recombination efficiency of mutant loxP sites
The chicken B cell line DT40 was used to test the recom-
bination efficiency of mutant loxP sites after chromo-
somal integration (Figure 2a). First a DT40 subclone, of
which is transgenic for the viral oncogene v-myb and has
a high gene conversion activity (unpublished results)
was stably transfected with the inducible MerCreMer
plasmid vector [7]. This results in a cell clone called
DT40 Cre 1. The MerCreMer mRNA is constitutively ex-
pressed in DT40 Cre 1, but the protein is inactive in the
absence of tamoxifen due to the fused HBD.
Both alleles of activation induced cytidine deaminase
(AID [9,10]) gene were disrupted in DT40 Cre 1 by
knockout constructs which are derived from pLoxPuro
and pLoxBsr. The phenotype of the AID -/- mutant cell
line will be described separately. To induce and verify
Cre mediated excision of the marker cassettes, the AID -
/- mutant was cultured in the presence of 4-hydroxy
tamoxifen, and recombination events between loxP_REBMC Biotechnology 2001, 1:7 http://www.biomedcentral.com/1472-6750/1/7
Figure 1
Mutant loxP sites and mutant loxP vectors. (a) The scheme of mutant loxP system is shown with sites for the rearrangement of
mutant loxP sites. Nucleotide changes in mutant loxP sequences are stressed by stars. (b) Maps and positions of multiple clon-
ing sites in the mutant loxP vectors, pLoxNeo, pLoxPuro and pLoxBsr. Each of the mutant loxP-flanked selectable marker
genes can be utilized as a BamHI cassette. pLoxNeo, pLoxPuro and pLoxBsr have unique SpeI sites outside of mutant loxP-
flanked region. pLoxPuro and pLoxBsr have unique NheI sites inside of mutant loxP-flanked region. These SpeI and NheI sites
are important for the combination of the mutant loxP vectors with pExpress (Figure 3). Location of the PCR primers specific
for the selectable marker genes (NE2, PU4, BS1) are shown by triangles.BMC Biotechnology 2001, 1:7 http://www.biomedcentral.com/1472-6750/1/7
Table I: Useful PCR primers
Primer (vector) Length Sequence
NE2 (pMloxNeo) 30 mer GGCTGACCGCTTCCTCGTGCTTTACGGTAT
PU4 (pMloxPuro) 29 mer CAGCGCCCGACCGAAAGGAGCGCACGACC
BS1 (pMloxBsr) 33 mer CGATTGAAGAACTCATTCCACTCAAATATACCC
forward (pExpress) 30 mer TTATTGTGCTGTCTCATCATTTTGGCAAAG
reverse (pExpress) 30 mer CTCTACAAATGTGGTATGGCTGATTATGAT
Figure 2
Quantitation of mutant loxP recombination following the induction of Cre recombinase. (a) Configuration of the AID locus in
an AID -/- DT40 mutant before and after Cre recombinase induction. The cell clone stably expresses a transfected MerCreMer
construct. PCR primers for detecting mutant-loxP recombination are shown together with the sizes of the resulting PCR prod-
ucts. (b) Time course of mutant loxP recombination. The cells were cultured for the indicated time in the presence of 0.05 mM
4-hydroxy tamoxifen for inducible-Cre activation. Crude extract of 500 cells were utilized for PCR reaction. The region down-
stream of loxP_LE, which is not affected by recombination, was amplified as a positive control.BMC Biotechnology 2001, 1:7 http://www.biomedcentral.com/1472-6750/1/7
and loxP_LE were quantified by PCR (Figure 2b). In the
absence of tamoxifen, recombination products between
loxP_RE and loxP_LE were not detected. Because of the
tight MerCreMer control, it was possible to work with
this cell line over a period of weeks without the occur-
rence of recombination events. One hour after tamoxifen
induction, mutant loxP recombination products were
easily detected. PCR products derived from the unrear-
ranged locus were only faintly present 12 hour after
tamoxifen addition and undetectable 24 hour after
tamoxifen addition. This indicates that deletion of mu-
tant loxP cassettes in virtually all cells of the culture re-
quired only one day of exposure to active Cre. Excision of
the mutant loxP flanked marker cassettes were also con-
firmed in loci other than AID. Several different DT40
knock-out mutants were cultured overnight with
tamoxifen for Cre induction, and were then subcloned by
limiting dilution. The frequency of subclones which have
deleted the selectable markers ranged from 60% to 100%
depending on the targeted locus (data not shown).
Expression cassette vector designed for conditional knock-
out
An expression vector pExpress was designed in which
the expression of a cloned cDNA is controlled by the
chicken β -actin promoter and a SV40 poly A signal (Fig-
ure 3a). The coding sequence of a cDNA can be inserted
into unique HindIII, NheI, EcoRV,  BglII, NcoI, SmaI
sites. A variety of restriction sites can be chosen for clon-
ing of the cDNA, because 1) the NheI site is compatible
with XbaI, SpeI and AvrII sites, 2) the BglII site is com-
patible with BamHI and BclI sites and 3) EcoRV and
SmaI digests generate blunt ends. The forward and re-
verse primers (Table 1I) can be utilized for sequencing
and PCR amplification of the inserted cDNA.
The pExpress cDNA expression cassette can be com-
bined with the selectable marker cassettes of the mutant
loxP vectors. pLoxNeo, pLoxPuro and pLoxBsr have
unique SpeI sites outside of the mutant loxP-flanked re-
gion (Figure 1b). pLoxPuro and pLoxBsr have unique
NheI sites inside of the mutant loxP-flanked region (Fig-
ure 1b). The SpeI and NheI are compatible with each oth-
er, and are for the insertion of the cDNA-expression SpeI
cassettes (Figure 3b). Although the NheI site is not
unique in pLoxNeo, a NheI-partial digest allows inser-
tion of the cDNA expression cassette as a SpeI fragment.
Cloning of the cDNA expression cassette into the SpeI
site of a mutant loxP vector generates an expression vec-
tor, in which only the selectable marker is flanked by mu-
tant loxP sites. If the cDNA expression cassette is cloned
into the NheI site of a mutant loxP vector, both of selecta-
ble marker and expression cassette are contained in the
region flanked by mutant loxP sites. This second con-
struct is useful if one intends to remove the cDNA ex-
pression cassette at a later time together with the marker
cassette.
The combination of a marker gene and an expression
cassette can be inserted as a BamHI cassette between the
5' and 3' target gene sequence of a knock-out construct
(Figure 3b). It is also possible to design knockout/com-
plementation constructs, in which the cDNA expression
cassette is derived from the target gene. After target inte-
gration of this construct, the expressed cDNA should
complement the gene disruption. Subsequent deletion of
the expression cassette by Cre induction will lead to a
complete gene knock-out.
Discussion
We have developed mutant loxP vectors for selectable
marker recycling and conditional knock-outs.
To produce a homozygous cell clone, two selectable
markers are normally required for the disruption of both
alleles, and one further selectable marker is needed for
phenotype complementation. Since three markers are
consumed for each knock-out study, disruption of multi-
ple genes is restricted by the number of available selecta-
ble marker.
Recycle of the mutant loxP marker cassettes solves this
problem and enables the addition of an unlimited
number of mutations to a cell clone. Genetic instability is
supposed to be low even after multiple rounds of selecta-
ble marker excision because the mutant loxP sites are in-
activated after recombination. The excision efficiency of
mutant loxP sites after overnight Cre induction ranged
between 60–100% when different loci were tested. This
variation is likely due to chromosomal context of the in-
tegration site. This excision efficiency may be easily im-
proved by longer exposure of cells to the active Cre-
recombinase.
Cre-mediated marker excision has previously been used
for animal and cell line knock-outs. Mice carrying loxP
flanked genes have for example been crossed with Cre-
transgenic mice which express Cre in a cell-type-specific
or inducible manner [11,12]. Tetracycline-regulated Cre
expression was used for a conditional RAD51 knock-out
in DT40 cells [13] and another inducible Cre, CreER,
which carries a HBD of mutated human oestrogen recep-
tor was used to excise markers after targeting of the
HPRT locus [14]. The advantage of MerCreMer, de-
scribed here, is in its tight control in addition to a high
level of induction [15]. In contrast to MerCreMer, Cre
carrying a single HBD has leaky recombination activity
even in the absence of the ligand (unpublished result).
Other advantages of our vectors are the use of mutant
loxP sites, the presence of multiple convenient restric-BMC Biotechnology 2001, 1:7 http://www.biomedcentral.com/1472-6750/1/7
tion sites flanking the marker cassettes and the use of the
strong and insertion site independent β -actin promoter.
The expression vector pExpress offers high flexibility
and many options when combined with the mutant loxP
vectors. First, any one of three selectable marker genes
Figure 3
Design of the cDNA expression vector and the conditional expression vectors. (a) Map and multiple cloning sites of expression
vector pExpress. After cloning of the cDNA coding sequence into pExpress, the expression cassette can be excised as a SpeI
cassette. Location of forward and reverse primers are shown by triangles. (b) Insertion of the cDNA expression cassette into
the mutant loxP vectors. Cloning of the expression cassette (SpeI cassette) into the SpeI site of mutant loxP vectors (pLoxNeo,
pLoxPuro and pLoxBsr) produces an expression vector whose selectable marker can be recycled. Cloning of the expression
cassette (SpeI cassette) into the NheI site of mutant loxP vectors (pLoxPuro and pLoxBsr) produces a vector in which a
selectable marker and an expression cassette is flanked by mutant loxP sites.BMC Biotechnology 2001, 1:7 http://www.biomedcentral.com/1472-6750/1/7
(neoR, puroR or bsr) can be chosen. Second, the cDNA
expression cassette can be located either inside or out-
side of mutant loxP-flanked region. Finally, expression
constructs can be designed for either random or targeted
integration.
The transfection of the cDNA expression cassette com-
bined with a targeting vector enables its insertion as a
single copy into a defined chromosomal location. This
should produce transfectants with similar expression
levels, as there is no variation due to differences in copy
numbers and insertion sites. The defined expression lev-
el in independent transfectants will be advantageous for
studies in which the effect of amino acid alterations is an-
alyzed by genetic complementation. Targeted integra-
tion of an expression cassette is also preferable over
random integration, if the subsequent excision is intend-
ed. This is due to the fact that the excision of a single copy
is easier to predict and to verify than the excision of mul-
tiple randomly integrated copies.
Conclusions
The mutant loxP system will further facilitate genetic
manipulation of chicken B cell line DT40. The mutant
loxP vectors have now been tested for a year, and have
been shown to function reliably in different chromosom-
al contexts. All genes in the vectors are driven by the
chicken β -actin promoter, which is also strong in mam-
malian cells including mouse ES cells. The vector cas-
settes should therefore be also useful for reverse genetics
of mammalian cells.
Materials and Methods
Oligo nucleotides
ML1 GATCCCCTACCGTTCGTATAGCATACATTATAC-
GAAGTTATTGATCAGGGCTAGCG
ML2 AATTCGCTAGCCCTGATCAATAACTTCG-
TATAATGTATGCTATACGAACGGTAGGG
ML3 CTAGCCCAGATCTATAACTTCGTATAGCATA-
CATTATACGAACGGTAGGGGATCCA
ML4 AGCTTGGATCCCCTACCGTTCGTATAATGTAT-
GCTATACGAAGTTATAGATCTGGG
LK5 AGCTTGGGCCACCGGCTAGCGGGGATATCG-
GGAGATCTC
LK6 CATGGAGATCTCCCGATATCCCCGCTAGCCGGT-
GGCCCA
LK9 CGGACTAGTGGCTCGAGGGAGATCTGGA
LK10 CTAGTCCAGATCTCCCTCGAGCCACTAGTCCG-
GGCC
Primer 1 [AI1] GTTTCTGTGCACCAGAGGGCT-
GAACAGTCA
Primer 2 [AI13] CTCCTTTCTTGGCTGGGTGAGAGGTC-
CATA
Linker preparation
Linker oligo-nucleotides were designed to minimize in-
ternal secondary structure. Linkers were prepared as fol-
lows: Oligo-nucleotides were dissolved into TE at a final
concentration of 100 pmol/µl. 40 µl of each oligo-nucle-
otide solution was combined, and incubated at 70°C for
5 minutes. 20 µl of 5 ×  annealing buffer (5 ×  annealing
buffer: 0.5 M Tris HCl pH 7.5, 0.35 M MgCl2) was added
to the combined oligo-nucleotide solution and was incu-
bated at 70°C for 5 minutes. After slowly cooling down to
room temperature for more than one hour, 10 pmol of
the annealed linker was ligated with 100 ng of plasmid
which had been digested by the appropriate restriction
enzymes without alkali-phosphatase treatment. Under
this condition, linker ligation was detected in more than
90% of bacterial transformants. The sequence of linker
was confirmed by sequencing of plasmid clones. As ex-
pected, linker concatemers were not observed in the
plasmid clones.
Construction of mutant loxP vectors
The linker ML1-ML2 was cloned between BamHI and
EcoRI sites of pBluescript KS (+). The resulting plasmid
was digested with NheI and HindIII and was ligated with
the linker ML3-ML4. The plasmid resulting from this li-
gation was digested with BglII, and was ligated with the
BamHI cassette of β -actin NeomycinR, β -actin Puromy-
cinR,  β -actin blasticidinR [16] to produce pLoxNeo,
pLoxPuro and pLoxBsr, respectively. The full-length se-
quences of the cassettes are available  [http://genet-
ics.hpi.uni-hamburg.de/dt40Reagents.html] .
Construction of pExpress
The BamHI-XhoI fragment of β -actin PuromycinR [16]
was cloned between the BamHI and the XhoI sites of pB-
luescript KS (+). The resulting plasmid was digested with
HindIII and NcoI, and was ligated with linker LK5-LK6
to produce plasmid bEX5. pBluescript KS (+) was digest-
ed with ApaI and SpeI, and ligated with linker LK9-
LK10. The plasmid resulting from this ligation was di-
gested by XhoI and BglII, and ligated with the XhoI-
BamHI fragment of bEX5 to produce pExpress.
Cre induction and PCR analysis
Medium containing 0.05 mM 4-hydroxy tamoxifen
(H7904, SIGMA) was used for Cre induction. Crude cellBMC Biotechnology 2001, 1:7 http://www.biomedcentral.com/1472-6750/1/7
extract for PCR was prepared from AID -/- DT40 cells af-
ter Cre induction as follows: The cells were once washed
with PBS, and were suspended into 1 ×  PCR buffer with 1
mg/ml proteinase K and 0.5% Tween 20. This solution
was incubated for 45 min at 56°C for proteinase K-medi-
ated proteolysis, followed by a 10 min incubation at 95°C
to inactivate the proteinase K. Crude extract correspond-
ing to 500 cells was used for each PCR reaction. PCR am-
plification was performed with Expand Long Template
PCR System (Roche): 2 min initial incubation at 93°C, 30
cycles consisting of 93°C for 10 sec, 65°C for 30 sec and
68°C for 5 min with cycle elongation of 20 sec per cycle,
and a final 5 min elongation step at 68°C.
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